Leukemia

The Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients aged 2 or older.

The Food and Drug Administration approved Asparlas (calaspargase pegol-mknl) as a component of a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia (ALL), according to the agency.

Former NFL coach discusses how cancer motivated him to appreciate life.

This week, we spoke with former NFL coach, motivational speaker and acute promyelocytic leukemia survivor Chuck Pagano about his journey with cancer, and what has inspired him to give back following his diagnosis.

Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.

Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.

The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.

The Food and Drug Administration (FDA) approved Daurismo (glasdegib) plus low-dose cytarabine (LDAC) chemotherapy to treat older, newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for chemotherapy.

A Venclexta combination was granted an accelerated approval to treat older patients with acute myeloid leukemia who are ineligible for chemotherapy.

The Food and Drug Administration (FDA) granted a priority review to quizartinib for the treatment of patients with relapsed or refractory FLT3-ITD acute myeloid leukemia (AML).

CLL is the most common type of leukemia in adults across the United State. Here's what you need to know about the disease.

Chronic lymphocytic leukemia can now be managed as a long-term condition, and there are new ways loved ones can help.

The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

I shared some advice with another soon-to-be caregiver.

Associating luck with any disease is unfair.

The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.